Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) EBIT (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed EBIT for 12 consecutive years, with -$19.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT fell 49.27% year-over-year to -$19.2 million, compared with a TTM value of -$66.5 million through Sep 2025, down 5.78%, and an annual FY2024 reading of -$68.5 million, down 150.49% over the prior year.
  • EBIT was -$19.2 million for Q3 2025 at Avalo Therapeutics, up from -$19.3 million in the prior quarter.
  • Across five years, EBIT topped out at $4.1 million in Q3 2022 and bottomed at -$32.8 million in Q1 2024.
  • Average EBIT over 5 years is -$14.1 million, with a median of -$13.3 million recorded in 2024.
  • The sharpest move saw EBIT skyrocketed 124.87% in 2022, then crashed 272.69% in 2024.
  • Year by year, EBIT stood at -$18.0 million in 2021, then soared by 50.71% to -$8.9 million in 2022, then rose by 13.51% to -$7.7 million in 2023, then tumbled by 73.82% to -$13.3 million in 2024, then plummeted by 44.23% to -$19.2 million in 2025.
  • Business Quant data shows EBIT for AVTX at -$19.2 million in Q3 2025, -$19.3 million in Q2 2025, and -$14.7 million in Q1 2025.